New drug cocktail shows promise against tough stomach cancer
NCT ID NCT01191697
First seen Nov 03, 2025 · Last updated Apr 29, 2026 · Updated 30 times
Summary
This study tested a combination of chemotherapy (CAPOX) and two targeted antibodies (trastuzumab and bevacizumab) in 37 adults with HER2-positive stomach or esophageal cancer that had spread. The goal was to see if the combo could shrink tumors safely. While the treatment helped control the disease, it is not a cure, and patients may need ongoing therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.